CN112587557B - Preparation for preventing and treating saprolegniasis of rassa schizopygma nojirima - Google Patents
Preparation for preventing and treating saprolegniasis of rassa schizopygma nojirima Download PDFInfo
- Publication number
- CN112587557B CN112587557B CN202011601109.2A CN202011601109A CN112587557B CN 112587557 B CN112587557 B CN 112587557B CN 202011601109 A CN202011601109 A CN 202011601109A CN 112587557 B CN112587557 B CN 112587557B
- Authority
- CN
- China
- Prior art keywords
- extract
- seabuckthorn
- sea buckthorn
- preparation
- saprolegniasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 41
- 241000229143 Hippophae Species 0.000 claims abstract description 150
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 117
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 46
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 38
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 34
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 34
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 34
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 34
- 239000001168 astaxanthin Substances 0.000 claims abstract description 34
- 239000002105 nanoparticle Substances 0.000 claims abstract description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims abstract description 20
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 235000017557 sodium bicarbonate Nutrition 0.000 claims abstract description 10
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims abstract description 10
- 235000003935 Hippophae Nutrition 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 238000001035 drying Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 13
- 238000007710 freezing Methods 0.000 claims description 11
- 230000008014 freezing Effects 0.000 claims description 11
- 238000000859 sublimation Methods 0.000 claims description 11
- 230000008022 sublimation Effects 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 238000009210 therapy by ultrasound Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 238000010298 pulverizing process Methods 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 7
- 108010059892 Cellulase Proteins 0.000 claims description 5
- 229940106157 cellulase Drugs 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 241000251468 Actinopterygii Species 0.000 abstract description 41
- 230000000694 effects Effects 0.000 description 27
- 150000003254 radicals Chemical class 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 230000001276 controlling effect Effects 0.000 description 8
- 241000233866 Fungi Species 0.000 description 6
- 241000233667 Saprolegnia Species 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002000 scavenging effect Effects 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 230000001338 necrotic effect Effects 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229910001369 Brass Inorganic materials 0.000 description 2
- 240000000950 Hippophae rhamnoides Species 0.000 description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- -1 and has antifungal Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000010951 brass Substances 0.000 description 2
- 150000001746 carotenes Chemical class 0.000 description 2
- 235000005473 carotenes Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930182486 flavonoid glycoside Natural products 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002088 nanocapsule Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- MGWGWNFMUOTEHG-UHFFFAOYSA-N 4-(3,5-dimethylphenyl)-1,3-thiazol-2-amine Chemical compound CC1=CC(C)=CC(C=2N=C(N)SC=2)=C1 MGWGWNFMUOTEHG-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241001444083 Aphanomyces Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000007163 Dermatomycoses Diseases 0.000 description 1
- 241001278356 Dictyuchus Species 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 241001117772 Elaeagnaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000001034 Frostbite Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000233658 Saprolegniaceae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000003929 dermatomycosis Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000002196 ecbolic effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a preparation for preventing and treating saprolegniasis of fishes in Tibet plateau, which comprises salt, baking soda, a sea buckthorn extract, salicylic acid and astaxanthin nanoparticles, wherein the sea buckthorn extract comprises a sea buckthorn fruit extract and a sea buckthorn leaf extract in a weight ratio of 2: 1. The preparation for preventing and treating saprolegniasis of Tibet plateau fishes can effectively prevent and treat saprolegniasis and reduce the death rate.
Description
Technical Field
The invention relates to the technical field of fish culture, in particular to a preparation for preventing and treating saprolegniasis of Tibet plateau fishes.
Background
Saprolegniasis, also called dermatomycosis, is caused by several species of the genera Saprolegnia (Saprolegnia), achlyria (achlyya), ophiocystis (Aphanomyces) and dictyosphaea (Dictyuchus) in the family saprolegniaceae (Saprolegniacae). The saprolegnia hypha is a tubular multikaryon without transverse partitions, is generally attached to the damaged part of aquatic animals like roots, has multiple branches and is fine, can penetrate into the damaged and necrotic skin and muscles to be called as inner hypha, and has the function of absorbing nutrition; the hyphae extending outside the body are coarse and have less branches, which can reach 3cm, and form a white floccule visible to the naked eye. The saprolegniasis occurs mainly because of secondary infection caused by the stress, the fish only has the influence of crowding, moving or other adverse environmental factors to cause body surface tissue injury, saprolegniasis zoospores in water are attached at random, and start to germinate on necrotic tissues to form hyphae, the hyphae can spread and invade nearby normal tissues besides parasitizing the necrotic tissues, secrete digestive ferment to decompose the covering of surrounding tissues, form sporangia at the tail end, release the zoospores into water, and spread everywhere through the water.
The ecological barrier and the safety barrier are important in China in the Tibetan region, known as the third pole of the earth. The literature data shows that the fish distributed in the area has 60 species and 13 subspecies, which belong to 3 orders, 5 families and 4 subfamilies, and 22 genera. Along with the degradation or loss of the habitat, the construction of dams and hydropower stations, the invasion of foreign species and the pollution to the environment, and the characteristics of slow growth, late sexual maturity and the like of fishes in the region, 12 threatened fishes (endangered and easily dangerous) exist, nearly 17 percent. 7 main fishes distributed in the Yalu Tibet Bujiang, and 5 fishes are in a threatened state, so that rescue and protection work for the threatened fishes in Tibet needs to be carried out urgently, and the germplasm continuity of the special fishes is ensured. The development of domestication and propagation of the Tibet plateau fishes is an effective means for preserving the germplasm resources of the Tibet plateau fishes. Water temperature for Tibetan fish culture: the water temperature is 9-20 ℃, the water temperature is in the range of the explosion of saprolegnia, and the Tibet plateau fishes are easy to cause mechanical damage in the process of fishing and transporting, so that the saprolegnia is caused to explode; in addition, wild fishes carry more parasites, and the fish body is damaged due to the breeding of the parasites, so that saprolegniasis outbreak is caused. In the breeding process of the Tibet plateau fishes, the parent is injected with an oxytocic, an agent egg and an agent sperm to cause mechanical damage to the fishes, so that the saprolegnia is bred. In the Tibetan fish culture process, as the culture fish size is increased, ponds need to be separated in time, and mechanical damage is easily caused in the transfer process, so that saprolegniasis outbreak is caused. Therefore, saprolegniasis frequently occurs in the process of domesticating and breeding the Tibet plateau fishes, and how to prevent and control the saprolegniasis of the Tibet plateau fishes becomes one of the main difficulties in the maintenance of the Tibet plateau fishes.
Disclosure of Invention
In view of the above, the invention aims to provide a preparation for preventing and treating saprolegniasis of Tibet plateau fishes.
In order to achieve the purpose, the technical scheme of the invention is realized as follows:
a preparation for preventing and treating saprolegniasis of Tibet plateau fishes comprises salt, baking soda, a sea buckthorn extract, salicylic acid and astaxanthin nanoparticles, wherein the sea buckthorn extract comprises a sea buckthorn fruit extract and a sea buckthorn leaf extract in a weight ratio of 2: 1.
Hippophae rhamnoides is a generic name of plants and fruits thereof, and is a deciduous shrub belonging to the genus Hippophae of the family Elaeagnaceae. The root, stem, leaf, flower and fruit of sea-buckthorn, especially the fruit of sea-buckthorn, contain abundant nutrient substance and biological active substance, the fruit of sea-buckthorn is rich in vitamin C, the content of fresh fruit of each hundred grams reaches 1600 milligrams, 35 times of orange, 250 times of pear, 400 times of apple, the name of king of vitamin, in addition also contain linoleic acid, protein, flavonoid substance, not only the food rich in nutrition, but also the good medicine for treating heart disease, hypertension and other diseases.
The seabuckthorn extract contains abundant active ingredients such as vitamin e, vitamin a, sod, flavone and the like, and the substances can well resist free radicals, so that the aging process of a human body becomes slower because the amount of the free radicals is small. Total Flavonoids (TFH) extracted from fructus Hippophae and folium Hippophae are a group of compounds containing 7 kinds of flavonoids, and can relieve angina pectoris and improve cardiac function and ischemic electrocardiogram. The anticancer effect of seabuckthorn fruit not only can be caused by immune mechanism or other ways, but also can directly inhibit cancer cells and block carcinogenic factors.
The effective component superoxide dismutase (SOD) of the seabuckthorn fruit has the function of removing free radicals in a human body, simultaneously can enhance the function of an immune system and regulate immunocompetent cells, is an effective immunomodulator, and has extremely obvious effects on improving the disease resistance of the human body and delaying the aging of the human body. The SOD content in the seabuckthorn fruit extract is 6 times of that of ginseng, the seabuckthorn fruit extract can block free radicals generated by peroxidation of substances in skin, can prevent premature aging of tissue and skin, can repair damaged cell tissues, can promote tissue regeneration and epithelial tissue healing, and has excellent effects on treating scald, burn, incised wound and frostbite clinically and domestically.
Folium Hippophae mainly contains nutrients and active ingredients such as flavonoids, crude fiber, polysaccharides, amino acids, vitamins, microelements, carotene, proteins, organic acids, chlorophyll, etc. The seabuckthorn leaf brass has 99 percent of flavonoid glycoside, is easier to dissolve in water than seabuckthorn fruit brass, has various pharmacological actions of increasing coronary blood flow, reducing myocardial oxygen consumption, inhibiting platelet aggregation and the like, and also has a research showing that the seabuckthorn leaf extract has the function of regulating blood fat similar to ginkgo flavonoid glycoside. The content of the water-soluble polysaccharide of the seabuckthorn leaves is 2.3-4.5%, and the water-soluble polysaccharide of the seabuckthorn can effectively remove oxygen free radicals in human bodies. The folium Hippophae contains multiple microelements such as Fe, Mg, Ca, Zn, Mo, K, etc., and has high content, magnesium and iron content higher than daily fruit and vegetable content, and carotene content of 19.1Mg/100 g.
The effective components in the seabuckthorn fruit extract and the seabuckthorn leaf extract are not completely the same, and the seabuckthorn fruit extract or the seabuckthorn leaf extract can make up the defect of singly using the seabuckthorn fruit extract or the seabuckthorn leaf extract after the seabuckthorn fruit extract and the seabuckthorn leaf extract are mixed according to a certain proportion, so that the effect of the seabuckthorn fruit extract or the seabuckthorn leaf extract is enhanced.
Salicylic acid is a plant willow bark extract, is a natural anti-inflammatory drug, and has antifungal, antipruritic and keratolytic effects in medicine. When the surface of fish body is infected with fungi, salicylic acid can also soften horny layer, when the horny layer is fallen off, hypha can also be fallen off at the same time, and in addition, salicylic acid can help other antifungal medicines to penetrate and inhibit fungi from growing.
Astaxanthin is a ketone carotenoid, is a chain-breaking antioxidant, has strong oxidation resistance, can eliminate nitrogen dioxide, sulfide, disulfide and the like, can reduce lipid peroxidation, effectively inhibit lipid peroxidation caused by free radicals, has physiological effects in various aspects such as inhibiting tumorigenesis, enhancing immunity, eliminating free radicals in vivo and the like, has good treatment effect on skin cancer caused by ultraviolet rays, has prevention and treatment effect on eye diseases caused by diabetes, and has wide application prospect in the aspects of health care products, medicines, cosmetics, food additives, aquaculture and the like. The strong antioxidant activity of astaxanthin is due to the fact that the astaxanthin can stabilize the structure of a membrane, reduce membrane permeability, limit a peroxide promoter from entering cells, and protect important molecules in the cells from oxidative damage, and meanwhile, the astaxanthin can potentially become an oxidant to induce oxidative stress. In addition, experiments show that the astaxanthin can increase the activity of antioxidant enzyme and the expression of protein, different doses of astaxanthin can obviously increase the expression of the protein of perhydrolase and superoxide dismutase in animal cells, the biological activity of the astaxanthin is obviously improved, and the substances have better antioxidant effect in vivo.
The astaxanthin nano-particles are particles with the particle size of less than 30nm developed by utilizing a nano-delivery system (NDS), so that the problems of the solubility and the stability of astaxanthin are solved, the astaxanthin nano-particles can effectively permeate skin, effective components are wrapped in nano-sized capsules, the nano-capsules are used as carriers, and the nano-capsules automatically and slowly release the effective components to skin tissues at a constant speed, so that the effective components can be maintained in effective concentration for a long time, stable effective components are obtained, and the absorption efficiency and the bioavailability are greatly increased.
Further, the salt, the baking soda, the sea buckthorn extract, the salicylic acid and the astaxanthin nanoparticles are in a weight ratio of (10-15): (10-15): (1-5): (0.5-1): (1-2).
Further, the salt, the baking soda, the sea buckthorn extract, the salicylic acid and the astaxanthin nanoparticles are prepared from the following raw materials in parts by weight: 15: 3: 0.5: 1.
further, the particle diameter of the sea buckthorn extract is 200-300 nm.
Further, the sea buckthorn extract is prepared by a method comprising the following steps:
1) weighing fresh fructus Hippophae and folium Hippophae, vacuum freeze drying fresh fructus Hippophae, pulverizing fresh folium Hippophae, and pretreating with cellulase for 20-40 min;
2) respectively adding the pretreated seabuckthorn fruit powder and seabuckthorn leaf pieces into a mixture according to a material-liquid ratio of 1: soaking in 10-20 lower alcohol solution at normal temperature for 1-2 hr, and performing ultrasonic treatment;
3) and then respectively adding purified water into the solution soaked with the seabuckthorn fruit powder and the seabuckthorn leaf fragments to ensure that the material-liquid ratio reaches 1: 30-40, and carrying out ultrasonic treatment for 6-12h at normal temperature;
4) extracting the treated solution, concentrating under reduced pressure, lyophilizing, and pulverizing to obtain fructus Hippophae extract and folium Hippophae extract;
5) mixing the seabuckthorn fruit extract and the seabuckthorn leaf extract according to the weight ratio of 2:1 to obtain the seabuckthorn extract.
Further, the vacuum freeze-drying of the seabuckthorn fruits comprises a pre-freezing stage, a sublimation drying stage and an analysis drying stage;
a pre-freezing stage: putting the cleaned fresh, natural-color and disease-free sea buckthorn fruits into a freezing tray for pre-freezing at the temperature of less than-35 ℃;
a sublimation drying stage: vacuumizing the vacuum freeze dryer for 10-15min, controlling the temperature of a heating shelf at 38-45 ℃ and the material temperature at-33 to-28 ℃, providing latent heat of sublimation, controlling the vacuum degree at 28-35pa and the time at 20-40 h;
and (3) analysis and drying stage: removing free water in fructus Hippophae during sublimation drying, and controlling material temperature below 50 deg.C to further remove bound water; and in the later period of analysis drying, the temperature difference between the shelf and the material is reduced, and when the temperature curve of the shelf and the temperature curve inside the material tend to be consistent, the drying is continued for 1.5-2.5 h.
The invention also provides a preparation method of the preparation for preventing and treating saprolegniasis of Tibet plateau fishes, which comprises the following steps:
1) weighing fresh fructus Hippophae and folium Hippophae, vacuum freeze drying fresh fructus Hippophae, pulverizing fresh folium Hippophae, and pretreating with cellulase for 20-40 min;
2) respectively adding the pretreated seabuckthorn fruit powder and seabuckthorn leaf pieces into a mixture according to a material-liquid ratio of 1: soaking in 10-20 parts of lower alcohol solution at normal temperature for 1-2h, and simultaneously performing 200-300W ultrasonic treatment;
3) and then respectively adding purified water into the solution soaked with the seabuckthorn fruit powder and the seabuckthorn leaf fragments to ensure that the material-liquid ratio reaches 1: 30-40, and carrying out ultrasonic treatment for 6-12h at normal temperature and 200-300W;
4) extracting the treated solution, concentrating under reduced pressure, lyophilizing, and pulverizing to obtain fructus Hippophae extract and folium Hippophae extract;
5) mixing the seabuckthorn fruit extract and the seabuckthorn leaf extract according to the weight part ratio of 2:1 to obtain a seabuckthorn extract;
6) and uniformly mixing the salt, the baking soda, the sea buckthorn extract, the salicylic acid and the astaxanthin nano particles according to the formula ratio to obtain preparation powder.
Further, the mass concentration of the lower alcohol is 90-95%.
Further, the lower alcohol is ethanol or butanediol.
The invention also provides a use method of the preparation for preventing and treating saprolegniasis of fishes in Tibet plateau, the preparation is prepared into powder and then directly sprinkled into a fishpond for fish culture, and 50-100g of the preparation is added into every 1L of water.
Compared with the prior art, the preparation for preventing and treating saprolegniasis of Tibet plateau fishes has the following advantages:
(1) the experimental data show that the preparation prepared by the formula has obvious curative effect on diseased rassa nojirimus nudus, probably because the sea buckthorn extract contains higher SOD, the preparation has the effects of promoting tissue regeneration and epithelial tissue healing on damaged cells and recovering the activity of diseased cells. In addition, the sea buckthorn extract and the astaxanthin can play a role in scavenging oxygen free radicals, enhance the capability of organisms in scavenging oxygen free radicals and resisting stress, enhance the resistance of fish bodies and reduce the damage of the fish bodies in stress or disease attack. In addition, the sea buckthorn extract also contains other effective components, so that the immunity of the organism is further improved. Moreover, the sea buckthorn extract is crushed into 300nm nanoparticles by a nanoscale ultrafine grinder, the astaxanthin is in the form of astaxanthin nanoparticles, and the nanoparticles are more beneficial to the effective components of the nanoparticles to penetrate through skin tissues of fish, so that the absorption efficiency and the bioavailability are greatly increased, and the saprolegniasis is more effectively prevented and treated. Salicylic acid is a natural anti-inflammatory drug, and can soften horny layer when the fish body surface is infected with fungi, so that the skin tissue can be penetrated by effective components, hypha can be simultaneously fallen off when the horny layer falls off, and in addition, the salicylic acid can help other antifungal drugs to penetrate and inhibit the growth of fungi.
(2) The experimental result also shows that the treatment effect of simultaneously adding the seabuckthorn fruit extract and the seabuckthorn leaf extract is better than that of singly using the seabuckthorn fruit extract or the seabuckthorn leaf extract, which indicates that the seabuckthorn fruit extract and the seabuckthorn leaf extract have complementary relationship and can enhance the treatment effect on saprolegniasis; and, the effect is best when the content of the seabuckthorn fruit extract is greater than that of the seabuckthorn leaf extract.
(3) The data of a comparison group show that the promotion effect exists among the sea buckthorn extract, the salicylic acid and the astaxanthin nanoparticles, and the prevention and treatment effect is reduced due to the lack of any one of the components; and the fact that the effect of directly using the astaxanthin and the effect of using the astaxanthin nanoparticles are also obviously different can be found by comparing the four groups, and the effect of using the astaxanthin nanoparticles is more excellent and is more beneficial to preventing and treating saprolegniasis.
Detailed Description
It should be noted that the embodiments and features of the embodiments may be combined with each other without conflict.
The present invention will be described in detail with reference to examples.
Example 1 preparation of sea buckthorn extract
1) Sea buckthorn fruit treatment
A pre-freezing stage: 10kg of fresh, natural-color and disease-free sea-buckthorn fruits after being cleaned are put into a freezing tray for pre-freezing at the temperature of minus 38 ℃;
a sublimation drying stage: vacuumizing the vacuum freeze dryer for 15min, controlling the temperature of a heating shelf at 40 ℃, controlling the temperature of materials at-30 ℃, providing latent heat of sublimation, controlling the vacuum degree at 30pa, and controlling the time at 35 h;
and (3) analysis and drying stage: removing free water in fructus Hippophae during sublimation drying, and controlling material temperature at 48 + -3 deg.C for further removing bound water; in the later period of analysis and drying, the temperature difference between the shelf temperature and the material is reduced, and when the temperature curve of the shelf and the temperature curve inside the material tend to be consistent, the drying is continued for 2 hours;
crushing: crushing the sea buckthorn berries subjected to vacuum freeze drying into 500-mesh powder for later use;
2) folium Hippophae processing
Weighing 10kg of fresh sea buckthorn leaves, crushing and pretreating with 1kg of cellulase for 25 min;
3) respectively adding the pretreated seabuckthorn fruit powder and seabuckthorn leaf pieces into a mixture according to a material-liquid ratio of 1: 10, soaking in 90% ethanol solution at normal temperature and 28 ℃ for 1h, and performing ultrasonic treatment at 300 w;
4) and then respectively adding purified water into the solution soaked with the seabuckthorn fruit powder and the seabuckthorn leaf fragments to ensure that the material-liquid ratio reaches 1: 40, carrying out ultrasonic treatment for 10 hours at the normal temperature of 28 ℃ by 300 w;
5) leaching the treated solution, concentrating under reduced pressure, lyophilizing, and pulverizing to 300nm with nanometer ultrafine pulverizer to obtain fructus Hippophae extract and folium Hippophae extract;
6) mixing the seabuckthorn fruit extract and the seabuckthorn leaf extract according to the weight ratio of 1:0, 1:1, 2:1, 1:2 and 0:1 respectively to obtain the seabuckthorn extract A, B, C, D, E.
EXAMPLE 2 preparation of the formulations
69g of the preparation is added into 1L of water, and salt, baking soda, sea buckthorn extract, salicylic acid and astaxanthin nanoparticles are mixed according to the formula shown in the table 1 to obtain preparation powder, so that preparation A, preparation B, preparation C, preparation D and preparation E are prepared.
TABLE 1 ingredient Table of the preparation
EXAMPLE 3 experiment of prevention and treatment of saprolegniasis with the preparation
(1) Material preparation
500 rassa naked nojirimus fishes with uniform body types, the body weight of about 1kg and saprolegniasis are purchased from a farm and are randomly and evenly divided into 10 groups, namely a preparation A group, a preparation B group, a preparation C group, a preparation D group, a preparation E group, a comparison two group, a comparison three group, a comparison four group and a blank control group.
TABLE 2 ingredient Table of comparative and control formulations
(2) Test of
10 groups of lasalopecuroides were raised separately at 6:00 and 7: 00 the preparation was added to 1L of water, and fed for 10 days, and the number of diseases and the mortality rate of each group were counted, and the results are shown in Table 3.
TABLE 3 comparison of results
From the above table, it can be found that the preparation prepared by the formula of the invention has an obvious cure effect on diseased rassa nojirimus nudus, probably because the hippophae rhamnoides extract contains higher SOD, the preparation has the effects of promoting tissue regeneration and epithelial tissue healing on damaged cells, and restoring the activity of diseased cells. In addition, the sea buckthorn extract and the astaxanthin can play a role in scavenging oxygen free radicals, enhance the capability of organisms in scavenging oxygen free radicals and resisting stress, enhance the resistance of fish bodies and reduce the damage of the fish bodies in stress or disease attack. In addition, the sea buckthorn extract also contains other effective components, so that the immunity of the organism is further improved. Moreover, the sea buckthorn extract is crushed into 300nm nanoparticles by a nanoscale ultrafine grinder, the astaxanthin is in the form of astaxanthin nanoparticles, and the nanoparticles are more beneficial to the effective components of the nanoparticles to penetrate through skin tissues of fish, so that the absorption efficiency and the bioavailability are greatly increased, and the saprolegniasis is more effectively prevented and treated. Salicylic acid is a natural anti-inflammatory drug, and can soften horny layer when the fish body surface is infected with fungi, so that the skin tissue can be penetrated by effective components, hypha can be simultaneously fallen off when the horny layer falls off, and in addition, the salicylic acid can help other antifungal drugs to penetrate and inhibit the growth of fungi.
The data of the preparations A-E can show that the treatment effect of simultaneously adding the seabuckthorn fruit extract and the seabuckthorn leaf extract is better than that of singly using the seabuckthorn fruit extract or the seabuckthorn leaf extract, which indicates that the seabuckthorn fruit extract and the seabuckthorn leaf extract have complementary relation and can enhance the treatment effect on saprolegniasis; and, the effect is best when the content of the seabuckthorn fruit extract is greater than that of the seabuckthorn leaf extract.
By comparing one group to four groups of data, the promotion effect exists among the sea buckthorn extract, the salicylic acid and the astaxanthin nanoparticles, and the prevention and treatment effect is reduced due to the lack of any one component; and the fact that the effect of directly using the astaxanthin and the effect of using the astaxanthin nanoparticles are also obviously different can be found by comparing the four groups, and the effect of using the astaxanthin nanoparticles is more excellent and is more beneficial to preventing and treating saprolegniasis.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the invention, and any modifications, equivalents, improvements and the like that fall within the spirit and principle of the present invention are intended to be included therein.
Claims (7)
1. An application of a pharmaceutical preparation in preparing a medicine for preventing and treating saprolegniasis of lasalopecurorima is characterized in that: the medicine consists of salt, baking soda, a sea buckthorn extract, salicylic acid and astaxanthin nanoparticles, wherein the sea buckthorn extract is a sea buckthorn fruit extract and a sea buckthorn leaf extract in a weight ratio of 2: 1; the salt, the baking soda, the sea buckthorn extract, the salicylic acid and the astaxanthin nanoparticles are in a weight ratio of (10-15): (10-15): (1-5): (0.5-1): (1-2); the particle diameter of the sea buckthorn extract is 200-300 nm.
2. The use of the pharmaceutical formulation of claim 1 for the preparation of a medicament for the prevention and treatment of saprolegniasis of lasalopecurorima, wherein: the salt, the baking soda, the sea buckthorn extract, the salicylic acid and the astaxanthin nanoparticles are prepared from the following raw materials in parts by weight: 15: 3: 0.5: 1.
3. the use of the pharmaceutical formulation of claim 1 for the preparation of a medicament for the prevention and treatment of saprolegniasis of lasalopecurorima, wherein: the sea buckthorn extract is prepared by the method comprising the following steps:
1) weighing fresh fructus Hippophae and folium Hippophae, vacuum freeze drying fresh fructus Hippophae, pulverizing fresh folium Hippophae, and pretreating with cellulase for 20-40 min;
2) respectively adding the pretreated seabuckthorn fruit powder and seabuckthorn leaf pieces into a mixture according to a material-liquid ratio of 1: soaking in 10-20 lower alcohol solution at normal temperature for 1-2 hr, and performing ultrasonic treatment;
3) and then respectively adding purified water into the solution soaked with the seabuckthorn fruit powder and the seabuckthorn leaf fragments to ensure that the material-liquid ratio reaches 1: 30-40, and carrying out ultrasonic treatment for 6-12h at normal temperature;
4) extracting the treated solution, concentrating under reduced pressure, lyophilizing, and pulverizing to obtain fructus Hippophae extract and folium Hippophae extract;
5) mixing the seabuckthorn fruit extract and the seabuckthorn leaf extract according to the weight ratio of 2:1 to obtain the seabuckthorn extract.
4. The use of the pharmaceutical formulation of claim 3 for the preparation of a medicament for the prevention and treatment of saprolegniasis of lasalopecurorima, wherein: the vacuum freeze-drying of the seabuckthorn fruits comprises a pre-freezing stage, a sublimation drying stage and an analysis drying stage;
a pre-freezing stage: putting the cleaned fresh, natural-color and disease-free sea buckthorn fruits into a freezing tray for pre-freezing at the temperature of less than-35 ℃;
a sublimation drying stage: vacuumizing the vacuum freeze dryer for 10-15min, controlling the temperature of a heating shelf at 38-45 ℃ and the material temperature at-33 to-28 ℃, providing latent heat of sublimation, controlling the vacuum degree at 28-35pa and the time at 20-40 h;
and (3) analysis and drying stage: removing free water in fructus Hippophae during sublimation drying, and controlling material temperature below 50 deg.C to further remove bound water; and in the later period of analysis drying, the temperature difference between the shelf and the material is reduced, and when the temperature curve of the shelf and the temperature curve inside the material tend to be consistent, the drying is continued for 1.5-2.5 h.
5. Use of a pharmaceutical formulation according to any one of claims 1-4 for the manufacture of a medicament for the prevention and treatment of saprolegniasis of rassa nojirimy, characterized in that: the medicine is prepared by the following method:
1) weighing fresh fructus Hippophae and folium Hippophae, vacuum freeze drying fresh fructus Hippophae, pulverizing fresh folium Hippophae, and pretreating with cellulase for 20-40 min;
2) respectively adding the pretreated seabuckthorn fruit powder and seabuckthorn leaf pieces into a mixture according to a material-liquid ratio of 1: soaking in 10-20 parts of lower alcohol solution at normal temperature for 1-2h, and simultaneously performing 200-300W ultrasonic treatment;
3) and then respectively adding purified water into the solution soaked with the seabuckthorn fruit powder and the seabuckthorn leaf fragments to ensure that the material-liquid ratio reaches 1: 30-40, and carrying out ultrasonic treatment for 6-12h at normal temperature and 200-300W;
4) extracting the treated solution, concentrating under reduced pressure, lyophilizing, and pulverizing to obtain fructus Hippophae extract and folium Hippophae extract;
5) mixing the seabuckthorn fruit extract and the seabuckthorn leaf extract according to the weight part ratio of 2:1 to obtain a seabuckthorn extract;
6) and uniformly mixing the salt, the baking soda, the sea buckthorn extract, the salicylic acid and the astaxanthin nano particles according to the formula ratio to obtain preparation powder.
6. The use of the pharmaceutical formulation of claim 5 for the preparation of a medicament for the prevention and treatment of saprolegniasis of lasalopecurorima, wherein: the mass concentration of the lower alcohol is 90-95%.
7. The use of the pharmaceutical formulation of claim 5 for the preparation of a medicament for the prevention and treatment of saprolegniasis of lasalopecurorima, wherein: the lower alcohol is ethanol or butanediol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011601109.2A CN112587557B (en) | 2020-12-29 | 2020-12-29 | Preparation for preventing and treating saprolegniasis of rassa schizopygma nojirima |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011601109.2A CN112587557B (en) | 2020-12-29 | 2020-12-29 | Preparation for preventing and treating saprolegniasis of rassa schizopygma nojirima |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112587557A CN112587557A (en) | 2021-04-02 |
| CN112587557B true CN112587557B (en) | 2022-04-19 |
Family
ID=75203849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011601109.2A Active CN112587557B (en) | 2020-12-29 | 2020-12-29 | Preparation for preventing and treating saprolegniasis of rassa schizopygma nojirima |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112587557B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213406A (en) * | 2015-10-08 | 2016-01-06 | 遵义清溪河富源生态渔业发展有限公司 | A kind of compositions of preventing and treating Squaliobarbus ourriculus fish molds |
| CN106387509A (en) * | 2016-09-23 | 2017-02-15 | 广州市联鲲生物科技有限公司 | Fish feed additive |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106798214A (en) * | 2017-01-24 | 2017-06-06 | 贵州省武陵山药用植物白芨开发有限公司 | A kind of hippophae rhamnoides beverage and preparation method thereof |
| CN107412322B (en) * | 2017-08-22 | 2021-03-26 | 中国水产科学研究院珠江水产研究所 | Composition for preventing and treating aquaculture saprolegniasis and preparation method thereof |
| CN108208793B (en) * | 2017-12-18 | 2021-05-04 | 山西金海利生物科技有限公司 | Preparation method of fermented sea buckthorn composition capable of improving intestinal immunity |
-
2020
- 2020-12-29 CN CN202011601109.2A patent/CN112587557B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105213406A (en) * | 2015-10-08 | 2016-01-06 | 遵义清溪河富源生态渔业发展有限公司 | A kind of compositions of preventing and treating Squaliobarbus ourriculus fish molds |
| CN106387509A (en) * | 2016-09-23 | 2017-02-15 | 广州市联鲲生物科技有限公司 | Fish feed additive |
Non-Patent Citations (1)
| Title |
|---|
| 低温季节的鱼病防治;张士刚;《农民致富之友》;19980415(第04期);第25页右栏 第1-2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112587557A (en) | 2021-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chojnacka et al. | Biologically active compounds in seaweed extracts-the prospects for the application | |
| Oršolić et al. | Synergystic antitumor effect of polyphenolic components of water soluble derivative of propolis against Ehrlich ascites tumour | |
| JP5319522B2 (en) | Walnut isolated extract, its acquisition and use | |
| KR20130039309A (en) | Garlic and yolk extract including functionality food composite for health | |
| KR20090098732A (en) | Anti-inflammatory, anti-oxidative or anti-bacterial compositions | |
| Jikah et al. | Moringa oleifera: a valuable insight into recent advances in medicinal uses and pharmacological activities | |
| Paiva et al. | Opuntia sp. cactus: Biological characteristics, cultivation and applications | |
| AU2021371794A1 (en) | Composition containing 5-aminolevulinic acid hydrochloride | |
| Srivastava et al. | Dynamic bioactive properties of nutritional superfood Moringa oleifera: A comprehensive review | |
| KR101827601B1 (en) | Cosmetic composition containing the extracts of moringa oleifera and morus having anti-oxidation and anti-inflammatory | |
| Triatmojo | The effect of nano-encapsulated herbal essential oils on poultry's health | |
| KR100478136B1 (en) | Extracts derived from plant that have anti-oxidation activity | |
| CN112587557B (en) | Preparation for preventing and treating saprolegniasis of rassa schizopygma nojirima | |
| KR20130045742A (en) | Method for producing feed for livestock adding nut pine essential oil and feed for livestock produced by the same | |
| Singh | Indian sea buckthorn | |
| KR101195577B1 (en) | Cosmetic composition for alleviating skin inflammation | |
| Anjum et al. | Lychee (Litchi chinensis): Biochemistry, panacea, and nutritional value | |
| Singh et al. | Phytochemistry and medicinal uses of moringa oleifera: an overview | |
| KR101478196B1 (en) | Composition for the prevention of foods from oxidation and for retarding the onset of diabetes comprsing of the extract of Cudrania tricuspidata as a main component | |
| CN113015432B (en) | Compositions comprising sulfated galactose and embodiments thereof | |
| CN111991546A (en) | A capsule containing Acer Truncatum Bunge extract and its preparation method | |
| KR20160117669A (en) | the manufacturing method of tea containing acetogenin of functional anti-cancer | |
| KR102192760B1 (en) | Methods for the manufacturing of water-soluble propolis powder and use thereof | |
| CN108743441A (en) | Anti-inflammatory stagnation resolvation infant's camellia soothing oil and preparation method thereof | |
| CN105077255A (en) | Cordyceps sobolifera health-care composite |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |